CtrlK
Theravance Biopharma
TBPH72
$9.280.00%$0.00
NASDAQ - As of Mar 14, 6:18 AM EDT Market Closed
TBPH72
$9.28
0.00%Performance History
arrow_drop_up7.40%
(+$0.64 )
| Key Stats | |
|---|---|
| Open | $9.39 |
| Prev. Close | $9.44 |
| EPS | -1.15 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $459.08M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 9.08 | 9.44 |
| 52 Week Range | 7.44 | 11.71 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Predicted: just now
info
Analyzed by 27 Wall Street experts, Theravance Biopharma 's 12-month projections average at $21.96, spanning from a high of $41.00 to a low of $8.00. This signifies an 136.66% shift from the current price of $9.28.
Analyst Ratings
Buy / Hold
| Buy | 2 | 50.00% | |
|---|---|---|---|
| Hold | 2 | 50.00% | |
| Sell | 0 | 0.00% |
•Ratings from: March•
Last updated: just now
•Total: 4info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.
Correlated Companies
About Theravance Biopharma (TBPH)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Rick E. Winningham M.B.A.
- Headquarters
- George Town
- Employees
- 111
- Exchange
- NASDAQ
Keep an eye on Theravance Biopharma
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Theravance Biopharma 's (TBPH) price per share?
The current price per share for Theravance Biopharma (TBPH) is $9.29. The stock has seen a price change of -$0.16 recently, indicating a -1.75% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Theravance Biopharma (TBPH)?
For Theravance Biopharma (TBPH), the 52-week high is $11.71, which is 26.12% from the current price. The 52-week low is $7.44, the current price is 24.8% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Theravance Biopharma (TBPH) a growth stock?
Theravance Biopharma (TBPH) has shown an average price growth of -1.65% over the past three years. It has received a score of 44 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Theravance Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Theravance Biopharma (TBPH) stock price performance year to date (YTD)?
As of the latest data, Theravance Biopharma (TBPH) has a year-to-date price change of -1.33%. Over the past month, the stock has experienced a price change of -2.06%. Over the last three months, the change has been -6.02%. Over the past six months, the figure is 14.07%. Looking at a longer horizon, the five-year price change stands at -62.62%.
help
Is Theravance Biopharma (TBPH) a profitable company?
Theravance Biopharma (TBPH) has a net income of -$55.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 29.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -49.06% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $57.42M, with a revenue growth rate of 11.84%, providing insight into the company's sales performance and growth. The gross profit is $16.8M. Operating income is noted at -$56.04M. Furthermore, the EBITDA is -$40.72M.
help
What is the market capitalization of Theravance Biopharma (TBPH)?
Theravance Biopharma (TBPH) has a market capitalization of $459.09M. The average daily trading volume is 9.25, indicating the stock's liquidity and investor engagement.